Sclerotherapy as a treatment modality for oral venous lake: protocol of use

Escleroterapia como modalidade de tratamento do lago venoso oral: protocolo de uso

ABSTRACT

Introduction: The venous lake is a venous ectasia that usually occurs on the lips and oral mucosa of the elderly. Although sclerotherapy is one of the most suitable treatments for this condition, dermatologists don't use this technique very often. Also, the concentration of the sclerosing agent, dose, and method of application are not standardized.

Objectives: This study aims to report the use of ethanolamine oleate 5% (EO5%) as a sclerosing agent to treat the oral venous lake and suggest a sclerotherapy protocol.

Methods: We used a standardized protocol to treat an oral venous lake in ten consecutive patients, based on the experience of a University Dermatology Clinic, specialized in Stomatology. EO5% was applied in deep and central intralesional injections, with a predetermined volume proportional to the lesion’s dimensions. Results: Six patients had total lesion regression with one session. Another three patients achieved satisfactory regression with two monthly sessions, and one patient required three monthly sessions. All participants reported edema or burning for one to three days.

Conclusion: The oral venous lake treatment with EO5% is a safe and effective technique that can be used in the dermatologist’s clinical practice.

Keywords: Venous Lake, Ethanolamine Oleate.

RESUMO

Introdução: o lago venoso é uma ectasia venosa que ocorre geralmente nos lábios e na mucosa oral de idosos. Embora a escleroterapia seja um dos tratamentos mais indicados para esta condição, esta técnica é pouco utilizada entre os dermatologistas. Além disso, a concentração do agente esclerosante, a dose e o modo de aplicação não estão padronizados.

Objetivos: relatar o uso do oleato de etanolamina a 5% (OE5%) como agente esclerosante para o tratamento do lago venoso oral e sugerir um protocolo de escleroterapia.

Métodos: foi utilizado em dez pacientes consecutivos um protocolo padronizado para tratamento de lago venoso oral, baseado na experiência de um Ambulatório Universitário de Dermatologia, especializado em Estomatologia. Aplicou-se o OE5%, em injeções intralesionais profundas e centrais, com volume predeterminado, proporcional às dimensões da lesão. Resultados: seis pacientes tiveram regressão total da lesão com uma sessão. Outros três pacientes alcançaram regressão satisfatória com duas sessões mensais e um paciente necessitou de três sessões mensais. Todos os participantes relataram edema ou queimação por um a três dias.

Conclusão: o tratamento do lago venoso oral com OE5% é uma técnica segura e eficaz que pode ser usada na prática clínica do dermatologista.

Palavras-chave: Escleroterapia, Lago Venoso, Oleato de Etanolamina.
INTRODUCTION
The venous lake is a venous ectasia that appears mainly on the lower lip, but it can also occur on the oral mucosa, being more frequent in the elderly. It is generally asymptomatic, of variable size, and may present with aesthetic impairment or bleeding after local trauma.

Sclerotherapy is a conservative technique consisting of intralesional injection of sclerosing agents that lead to inflammation of the vessels followed by occlusion and vascular sclerosis, resulting in lesion regression.

Although sclerotherapy is affordable, effective, and has a low risk of complications, the concentration of the sclerosing agent, dose, and method of application are not entirely standardized in the treatment of the venous lake.

This article aims to report the use of 5% ethanolamine oleate (OE5%) as a sclerosing agent for the treatment of the oral venous lake, both on the lip and oral mucosa, and to suggest a sclerotherapy protocol based on the experience of our clinical center.

METHODOLOGY
Box 1 describes the treatment protocol for oral venous lake using OE5% with a sclerosing agent (Ethamolin®, Farmoquímica - Brazil). We use the technique in 10 consecutive patients attending the Stomatology Outpatient Clinic of the Department of Dermatology at UNIFESP during 2019 (Box 1).

The procedure is contraindicated in pregnancy, uncontrolled diabetics, and infection at the application site.

RESULTS
Most patients were women (7/10) and over 50 years old (9/10). The venous lake was observed in the lower lip in 6/10 patients, in the upper lip in 1/10 patients, and in the oral mucosa in 3/10 patients. The size varied between 3 mm to 10 mm in diameter. The patients reported asymptomatic lesions with an onset time greater than five years. Some individuals described accidental local trauma with mild bleeding.

Most patients (6/10) needed only one application of OE5% (Figure 1), while other patients required two or three monthly sessions. We observed complete regression of the lesions in the vast majority of cases (9/10), and in one case, the patient was satisfied with only a partial regression.

Most patients reported discomfort after applying the sclerosing agent, such as pain, edema, redness, and burning (Figure 2). These symptoms lasted from one to three days. In one case, ulceration and local necrosis occurred due to the application being more superficial, resolving in seven to ten days without leaving scars (Figure 3).

DISCUSSION
The diagnosis of the oral venous lake is based on the clinical characteristics and history of the lesion. Vitro pressure, polarized light dermoscopy, aspiration, and imaging exams can also constitute accessory resources for diagnosis and treatment planning in some cases.

Histologically, dilated, thin-walled venules located close to the epithelial tissue can be observed. The differential diagnosis includes melanocytic nevus, melanotic macule, malignant melanoma, pyogenic granuloma, and Kaposi’s sarcoma.

<table>
<thead>
<tr>
<th>Box 1. Protocol for the treatment of oral venous lake</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. The patient is informed about the procedure, the likely resulting discomfort, and possible local changes after treatment.</td>
</tr>
<tr>
<td>2. Local asepsis is performed with 2% aqueous chlorhexidine solution for lesions on the lip. Lesions located in the oral cavity use mouthwash with 0.12% chlorhexidine for 60 seconds.</td>
</tr>
<tr>
<td>3. The dose of OE5% is calculated according to the size of the lesion: lesion up to 5 mm in its longest length receives up to 0.1 ml of intralesional OE5%; for each additional 1 mm in the size of the lesion, the proportional quantity in ml is added to the initial dose.</td>
</tr>
<tr>
<td>4. With an insulin syringe, the sclerosing agent is applied to the center and the deepest portion of the vascular lesion, avoiding superficial infiltration. Aspiration is not necessary, as bleeding is visible from the puncture inside the vessel. Local anesthesia is unnecessary.</td>
</tr>
<tr>
<td>5. Application should be slow and gradual to avoid rupture of blood vessels and local discomfort.</td>
</tr>
<tr>
<td>6. For lesions larger than 1 cm, more than one injection is performed to distribute the drug homogeneously.</td>
</tr>
<tr>
<td>7. Patients should be evaluated after one week.</td>
</tr>
<tr>
<td>8. The procedure can be repeated at 4-week intervals until achieving a satisfactory result.</td>
</tr>
</tbody>
</table>
The treatment modalities for venous lake include electrocoagulation, surgical excision, laser therapy, infrared coagulation, cryotherapy, and sclerotherapy. OE5% is one of the most widely used sclerosing agents in treating vascular lesions. The literature describes it as a safe and effective method for injuries located in different body regions.

Our outpatient clinic has used sclerotherapy to treat the oral venous lake for more than ten years with good results. We presented ten patients treated consecutively and who reached a complete resolution in 90% of cases. We suggest this protocol can guide the definition of the drug’s necessary amount regarding the lesion’s size. The application is performed in the outpatient clinic, and it does not require the use of the operating room. The technique is quick and does not require block anesthesia. The most uncomfortable adverse event was the temporary swelling after application, which usually occurs in all cases. It is easily

Table 1: Demographic and clinical characteristics of oral venous lake lesions

<table>
<thead>
<tr>
<th>Case</th>
<th>Age</th>
<th>Gender</th>
<th>Site</th>
<th>Size</th>
<th>N of applications</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>&gt;50</td>
<td>F</td>
<td>LL</td>
<td>4mm</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>&gt;50</td>
<td>F</td>
<td>OM</td>
<td>3mm</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>&gt;50</td>
<td>M</td>
<td>LL</td>
<td>6mm</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>&gt;50</td>
<td>F</td>
<td>OM</td>
<td>5mm</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>&gt;50</td>
<td>F</td>
<td>LL</td>
<td>4mm</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>&lt;50</td>
<td>F</td>
<td>LL</td>
<td>8mm</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>&gt;50</td>
<td>M</td>
<td>LL</td>
<td>6mm</td>
<td>2</td>
</tr>
<tr>
<td>8</td>
<td>&gt;50</td>
<td>F</td>
<td>UP</td>
<td>5mm</td>
<td>1</td>
</tr>
<tr>
<td>9</td>
<td>&gt;50</td>
<td>M</td>
<td>LL</td>
<td>10mm</td>
<td>1</td>
</tr>
<tr>
<td>10</td>
<td>&gt;50</td>
<td>F</td>
<td>OM</td>
<td>10mm</td>
<td>3</td>
</tr>
</tbody>
</table>

LL = lower lip; UP = upper lip; OM = oral mucosa

**Figure 1:** Clinical images: A) before treatment and B) after 4 weeks of treatment with a single dose of 0.2% intralesional OE5%

**Figure 2:** Edema after 5 minutes of infiltration of 0.1 ml of OE5%. The patient reported feeling a slight burning sensation

**Figure 3:** Ulceration and necrosis after 2 weeks of superficial intralesional infiltration of OE5% 0.1 ml in 2 lesions on the lower lip

explained considering the inflammatory process caused by the sclerosing agent.

The most observed complication was the ulceration's appearance due to a very superficial application, which also occurred in some cases throughout our experience. The resolution occurred in 15 days without leaving a scar. The injection technique must be deep in the vascular lesion center to avoid this complication. Using a greater quantity of the sclerosing agent than what is recommended or its overflow may cause ulceration.

The recommended OE5% limit dose for sclerotherapy is up to 2 ml per application. Other complications reported in the literature include hemoglobinuria and hemolytic renal failure cases, but their occurrence was limited to the use of doses greater than 9.6 ml of OE5%.

This protocol’s description aims to share the authors’ experience and the best practices accumulated in the last ten years in a specialized Stomatology service. The protocol can help professionals maximize the chances of success and minimize the appearance of adverse events in the oral venous lake treatment.

CONCLUSION

The oral venous lake treatment with OE5% is a safe and effective technique that can be used in the dermatologist’s clinical practice.

REFERENCES


AUTHORS’ CONTRIBUTION:

Dalva Regina Neto Pimentel | ORCID 0000-0001-7783-4810
Study design and planning; preparation and writing of the manuscript; data collection, analysis, and interpretation; critical literature review; critical revision of the manuscript.

Rafael Tomaz Gomes | ORCID 0000-0001-8775-2173
Preparation and writing of the manuscript; data collection, analysis, and interpretation; critical literature review; critical revision of the manuscript.

Cleonice Hirata | ORCID 0000-0002-6336-961X
Study design and planning; data collection, analysis, and interpretation; critical revision of the manuscript.